Traditional Chinese Medicine Syndrome Distribution in Chronic Hepatitis B Populations: A Systematic Review

Abstract

Many patients with chronic hepatitis B (CHB) seek help from traditional Chinese medicine (TCM). TCM treatment is based on syndrome differentiation. This study aimed to investigate the syndrome distribution in populations of CHB patients. The pre-specific search strategy was set, and 93 studies (20,106 participants) were identified by electronic and hand searches. The methodological quality of included studies was assessed. Data on syndrome distribution and correlations between syndromes and severity of CHB, were extracted and analyzed. Forty-seven syndromes were identified under 24 different syndrome diagnosis systems for CHB. The majority of included studies reported Liver Depression and Spleen Deficiency (LDSD) (52.54% of studies) or Liver-Gallbladder Dampness Heat (LGDH)/Dampness-Heat Obstructing Middle Energizer (DHME) (32.20%) as the major syndromes in CHB patients without cirrhosis. Pooled analysis revealed that LDSD and LGDH/DHME accounted for 61.19% of participants without cirrhosis. In addition, Liver-Kidney Yin Deficiency (LKYinD) (40.99%) and Spleen-Kidney Yang Deficiency (SKYangD) (40.43%) syndromes were common in patients with severe CHB. The percentage of patients with Blood Stasis syndrome increased as the disease progressed to cirrhosis (32.09%). To conclude, LDSD and LGDH/DHME syndromes are found in a significant majority of CHB patients, particularly in the early stages. LKYinD, SKYangD and Blood Stasis dominate in patients at more advanced stages. More epidemiological studies of high methodological quality on syndrome distribution in CHB and standardization of syndrome differentiation for CHB are required to confirm the trends indicated by the studies reviewed here; confirming these trends can increase the efficacy of treatment and give guidance to doctors.

Hydroxysafflor yellow A suppresses liver fibrosis induced by carbon tetrachloride with high-fat diet by regulating PPAR-γ/p38 MAPK signaling

“…Although numerous Western medications have been used to inhibit the progression of hepatic fibrosis (Zeng et al, 2011), none have achieved satisfactory therapeutic effects. Therefore, we have focused on traditional Chinese herbal medications, which generally have negligible side effects compared with Western medications.…”

Comparison of Telbivudine and Entecavir Therapy on Nephritic Function and Drug Resistance in Patients with Hepatitis B Virus-Related Compensated Cirrhosis

“…Sustained suppression or elimination of HBV replication is the ultimate goals of HBV treatment [22,23]. Nucleotide analogues are currently regarded as standard treatment for patients with chronic hepatitis B over 10 years by effectively inhibiting HBV virus replication to prevent development of hepatic complications, as well as cirrhosis, hepatic decompensation, and HCC.…”

Investigation of therapeutic effect of Longchai Formula Granule on chronic hepatitis B patients: A double-blind, controlled and randomized clinical trial

“…Antiviral and liver-protecting therapy is a standardized treatment method that can reduce morbidity and mortality HBV infected patients [5][6]. Since a significant proportion of CHB patients fail to get satisfactory treatment from conventional medicine, so many CHB patients seek help from complementary and alternative medicine (CAM), especially traditional Chinese medicine (TCM) [7]. The Chinese pharmacopoeias contain numerous specific medicines and formulas, and numerous studies show that several herbs have antiviral activity and can prevent viral infection.…”